Posted by Michael Wonder on 13 Mar 2024
Sumitomo Pharma announces availability of Orgovyx (relugolix) in Canada, the first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
12 March 2024 - Sumitomo Pharma announced today that Orgovyx (relugolix), an oral gonadotropin-releasing hormone receptor antagonist, is now available for prescription in Canada for the treatment of adult patients with advanced prostate cancer.
The availability of Orgovyx follows the Health Canada approval of Orgovyx in October 2023 for the treatment of advanced prostate cancer.
